Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

20
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
20
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

245
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
245
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

235
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
235
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

41
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
41
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

12
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
12
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

29
Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Nutraceuticals in the clinical management of women with breast cancer; a narrative review].

Semergen·2026
Same author

[Recommendations for the management of menopausal vasomotor symptoms in clinical practice].

Semergen·2025
Same author

Management of menopausal hot flushes. Recommendations from the Spanish Menopause Society.

European journal of obstetrics & gynecology and reproductive biology: X·2025
Same author

Improvement in menopausal symptoms with a nutritional product containing evening primrose oil, hop extract, saffron, tryptophan, vitamins B6, D3, K2, B12, and B9.

European review for medical and pharmacological sciences·2023
Same author

10-month retrospective study on compliance and tolerability of the drospirenone-only pill.

European review for medical and pharmacological sciences·2023
Same author

Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA.

Climacteric : the journal of the International Menopause Society·2023

Related Experiment Video

Updated: Aug 1, 2025

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
03:55

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis

Published on: October 18, 2024

238

Sequential treatment in vulvovaginal atrophy.

S Palacios1

  • 1Palacios Institute of Women's Health, Madrid, Spain.

Climacteric : the Journal of the International Menopause Society
|April 27, 2023
PubMed
Summary

Vulvovaginal atrophy (VVA) management requires long-term strategies. Estrogen receptor treatments are recommended first-line, followed by moisturizers or energy-based therapies for improved quality of life.

Keywords:
Vulvovaginal atrophylaser and radiofrequencyospemifeneprasteronesequential treatmentvaginal estrogensvaginal moisturizers

More Related Videos

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

1.8K
Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

11.5K

Related Experiment Videos

Last Updated: Aug 1, 2025

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
03:55

Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis

Published on: October 18, 2024

238
Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

1.8K
Vessel-sparing Excision and Primary Anastomosis
08:09

Vessel-sparing Excision and Primary Anastomosis

Published on: January 7, 2019

11.5K

Area of Science:

  • Gynecology
  • Women's Health
  • Vaginal Health

Background:

  • Vulvovaginal atrophy (VVA) is a chronic condition impacting quality of life and sexual health.
  • Effective management necessitates long-term, sequential treatment strategies.
  • Current treatments include topical products, hormone therapy, DHEA, ospemifene, and energy-based options.

Purpose of the Study:

  • To review and categorize current therapeutic options for vulvovaginal atrophy.
  • To propose a sequential treatment approach based on efficacy, safety, and patient adherence.
  • To highlight the role of estrogen receptor-acting treatments as a primary therapeutic strategy.

Main Methods:

  • Literature review of current vulvovaginal atrophy treatments.
  • Analysis of treatment mechanisms, efficacy, and safety profiles.
  • Development of a tiered treatment recommendation framework.

Main Results:

  • Estrogen receptor-targeting treatments are proposed as the first-line option due to physiological benefits and efficacy.
  • Vaginal moisturizers are effective for symptom relief but do not address underlying conditions.
  • Energy-based treatments (laser, radiofrequency) present a third option, with considerations for cost and long-term safety data.

Conclusions:

  • A sequential treatment approach prioritizing estrogen receptor therapies is recommended for vulvovaginal atrophy.
  • Vaginal moisturizers and lubricants can be used adjunctively or as alternatives.
  • Further research on the long-term safety and cost-effectiveness of energy-based treatments is warranted.